GlassScriptPhysician profile
David Aaron Weinstein
NPI 1194046144
$1,985.01
in general payments reported to CMS, 2019-2025
25 companies · $841 in 2025
The $841 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.19 · 2022: $26.03 · 2023: $382 · 2024: $637 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,654 · Travel and Lodging: $185 · Education: $21.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,654.15 |
| Travel and Lodging | $185.43 |
| Education | $21.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $292.79 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $252.06 | 2019-2025 | Dupixent, Libtayo |
| Smith+Nephew, INC. | $185.43 | 2025 | |
| Abbvie INC. | $169.04 | 2023-2025 | Rinvoq |
| Arcutis Biotherapeutics, INC. | $139.59 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $93.56 | 2023-2025 | Sotyktu |
| Pfizer INC. | $90.14 | 2023-2025 | |
| Biofrontera INC. | $82.36 | 2023-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Ucb, INC. | $73.29 | 2025 | Bimzelx |
| Organon LLC | $68.13 | 2025 | |
| Dermavant Sciences, INC. | $66.19 | 2022-2024 | Vtama |
| Incyte Corporation | $63.15 | 2024-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $61.62 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.20 | 2023-2024 | Spevigo |
| Novartis Pharmaceuticals Corporation | $45.88 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $42.20 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Galderma Laboratories, L.P. | $36.77 | 2025 | Nemluvio |
| Surgenex LLC | $26.78 | 2025 | Pellograft, Renograft, Surgraft |
| Journey Medical Corporation | $24.92 | 2023 | |
| Teleflex LLC | $24.47 | 2025 | Barrigel |
| Lilly USA, LLC | $22.62 | 2025 | Taltz, Ebglyss |
| Verrica Pharmaceuticals INC. | $22.23 | 2025 | Ycanth |
| Leo Pharma INC. | $20.10 | 2023 | Adbry |
| Calyxo, INC. | $16.13 | 2025 | Cvac Aspiration System |
| Organogenesis INC. | $15.36 | 2024 | Affinity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Weinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.